We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





New COVID-19 Mass Screening Method Could Be 20 Times Cheaper Than Individual Testing

By LabMedica International staff writers
Posted on 22 Oct 2020
Using a new mathematical approach to screen large groups for COVID-19 could be around 20 times cheaper than individual testing, suggests a study by researchers at The University of Edinburgh (Edinburgh, UK).

Applying a recently created algorithm to test multiple samples in one go reduces the total number of tests needed, lowering the cost of screening large populations for COVID-19, according to the researchers. More...
This novel approach will make it easier to spot outbreaks early on. Initial research has shown that it is highly effective at identifying positive cases when most of the population is negative.

The researchers developed the method - called the hypercube algorithm - and conducted the first field trials in Africa. Tiny quantities taken from individual swabs were mixed to create combined samples and then tested. The team showed that a single positive case could still be detected even when mixed with 99 negative swab results. If this initial test highlighted that the mixed sample contained positive cases, then researchers used the algorithm to design a further series of tests. This enabled them to pinpoint individual positive swab results within the combined sample, making it easy to identify people who are infected. If the initial test results indicated that there were no positive cases in the mixed sample, then no follow-up action was needed. The new method is best suited to regular screening of a population - rather than testing individual patients - and may help to significantly lower testing costs, according to the researchers.

“We hope our method will enable regular, cost-effective screening in multiple contexts. By doing so, it could be a game changer in helping us to overcome the COVID-19 pandemic,” said the University’s inaugural Higgs Chair of Theoretical Physics, Professor Neil Turok.

Related Links:
The University of Edinburgh


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: ARIA can appear as brain swelling or small hemorrhages on MRI scans and remains difficult to predict before treatment begins (Reisa A, Sperling et al, via Wikimedia Commons, CC BY 4.0)

Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug

New antibody therapies for Alzheimer’s disease have shown promise in slowing disease progression, but their broader use has been limited by a common side effect known as amyloid-related imaging abnormalities (ARIA).... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.